- Home
- KBR vs INDV Comparison
KBR vs INDV Comparison
Compare KBR & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KBR | INDV |
|---|---|---|
| Founded | 1901 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.2B |
| IPO Year | 2006 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KBR | INDV |
|---|---|---|
| Price | $34.65 | $36.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $44.29 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 1.3M | 1.3M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | 15.05 | ★ 8100.00 |
| EPS | 1.55 | ★ 1.67 |
| Revenue | ★ $5,767,000,000.00 | $1,239,000,000.00 |
| Revenue This Year | $3.48 | $7.50 |
| Revenue Next Year | $5.59 | $5.07 |
| P/E Ratio | $22.61 | ★ $21.19 |
| Revenue Growth | 2.27 | ★ 4.29 |
| 52 Week Low | $29.94 | $22.78 |
| 52 Week High | $47.62 | $42.81 |
Technical Indicators
Market Signals| Indicator | KBR | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 37.38 | 51.18 |
| Support Level | $34.44 | $35.78 |
| Resistance Level | $38.36 | $38.12 |
| Average True Range (ATR) | 1.01 | 0.93 |
| MACD | -0.09 | 0.19 |
| Stochastic Oscillator | 27.25 | 71.15 |
Price Performance
Historical ComparisonAbout KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is a global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: mission technology solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 36,000 people. The firm generated $7.8 billion in revenue in 2025.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).